Robert J Webster

US Patent:

8124101, Feb 28, 2012

Filed:

Jun 1, 2005

Appl. No.:

11/628292

Inventors:

Peter Palese - Leonia NJ, US
Adolfo Garcia-Sastre - New York NY, US
Richard J. Webby - Memphis TN, US
Juergen A. Richt - Ames IA, US
Robert G. Webster - Memphis TN, US
Kelly M. Lager - Colo IA, US

Assignee:

Mount Sinai School of Medicine - New York NY
St. Jude Children's Research Hospital - Memphis TN
The United States of America as represented by The Secretary of Agriculture - Washington DC

International Classification:

A61K 39/145
A61K 49/00

US Classification:

4242061, 4242091, 424 92

Abstract:

The present invention relates, in general, to attenuated swine influenza viruses having an impaired ability to antagonize the cellular interferon (IFN) response, and the use of such attenuated viruses in vaccine and pharmaceutical formulations. In particular, the invention relates to attenuated swine influenza viruses having modifications to a swine NS1 gene that diminish or eliminate the ability of the NS1 gene product to antagonize the cellular IFN response. These viruses replicate in vivo, but demonstrate decreased replication, virulence and increased attenuation, and therefore are well suited for use in live virus vaccines, and pharmaceutical formulations.

US Patent:

20130034581, Feb 7, 2013

Filed:

Nov 23, 2011

Appl. No.:

13/304175

Inventors:

Peter Palese - Leonia NJ, US
Adolfo Garcia-Sastre - New York NY, US
Richard J. Webby - Memphis TN, US
Juergen A. Richt - Ames IA, US
Robert G. Webster - Memphis TN, US
Kelly M. Lager - Colo IA, US

International Classification:

C12N 7/04
C12N 5/073
A61K 39/12
C12N 5/07

US Classification:

4241991, 435236, 435350, 435349

Abstract:

The present invention relates, in general, to attenuated swine influenza viruses having an impaired ability to antagonize the cellular interferon (IFN) response, and the use of such attenuated viruses in vaccine and pharmaceutical formulations. In particular, the invention relates to attenuated swine influenza viruses having modifications to a swine NS1 gene that diminish or eliminate the ability of the NS1 gene product to antagonize the cellular IFN response. These viruses replicate in vivo, but demonstrate decreased replication, virulence and increased attenuation, and therefore are well suited for use in live virus vaccines, and pharmaceutical formulations.

US Patent:

45527580, Nov 12, 1985

Filed:

Dec 20, 1983

Appl. No.:

6/563372

Inventors:

Brian R. Murphy - Bethesda MD
Robert M. Chanock - Bethesda MD
Robert G. Webster - Memphis TN
Virginia S. Hinshaw - Germantown TN

Assignee:

St. Jude Children's Research Hospital - Memphis TN

International Classification:

A61K 39145

US Classification:

424 89

Abstract:

A method of producing a live attenuated vaccine useful in humans which comprises producing an influenza A reassortant virus by gene exchange between an avian influenza virus parent and a human influenza virus parent and then excluding the internal genes (that code for non-surface viral proteins) of the human influenza virus parent from the reassortant by temperature selection and excluding the surface antigen genes of the avian influenza A virus parent by antibodies.

US Patent:

45527571, Nov 12, 1985

Filed:

Dec 20, 1983

Appl. No.:

6/563370

Inventors:

Brian R. Murphy - Bethesda MD
Robert M. Chanock - Bethesda MD
Robert G. Webster - Memphis TN
Virginia S. Hinshaw - Germantown TN

Assignee:

St. Jude Children's Research Hospital - Memphis TN

International Classification:

A61K 39145

US Classification:

424 89

Abstract:

A method of producing a vaccine useful in animals which comprises producing a reassortment by gene exchange from an avian influenza A virus parent and an animal influenza A virus parent and then selecting for the reassortant containing two animal surface antigen genes and six avian internal genes by temperature and antibodies.